Table 2

List of CD27/CD70 targeting agents in ongoing clinical trials

Name of the compoundMechanism of actionTumour typePhase of clinical trial developmentCompanyReference/trial number
Varlilumab+atezolizumab in combination with radiation therapyFully human IgG1 CD27 agonistic mAb+fully human IgG1 inhibitory mAb targeting PD-L1Stage III–IV NSCLC, metastatic NSCLC, unresectable NSCLCPhase I, recruitingRutgers, The State University of New Jersey+NCINCT04081688
Varlilumab+IMA950 vaccine+Poly ICLC (Hiltonol)Fully human IgG1 CD27 agonistic mAb+multipeptide vaccine containing 11 tumour-associated peptidesGlioma, malignant glioma, astrocytoma grade II, oligodendroglioma, astrocytic oligoastrocytomaPhase I, recruitingCelldex TherapeuticsNCT02924038
Anti-hCD70 CARAnti-hCD70 CAR transduced PBL targeting CD70Pancreatic cancer, RCC, breast cancer, melanoma, ovarian cancerPhase I/II, recruitingNCINCT02830724
4SCAR70Fourth-generation CAR-T cell targeting CD70B-cell malignanciesPhase I/II, recruitingShenzhen Geno-Immune Medical InstituteNCT03125577
Varlilumab+nivolumabFully human IgG1 CD27 agonistic mAb+fully human IgG4 mAb targeting PD-1B-cell lymphomaPhase II, recruitingNCINCT03038672
Varlilumab+DC vaccinations+standard of care RT and TMZFully human IgG1 CD27 agonistic mAb+human pp65 CMV DCs+radiotherapy+alkylating agentGlioblastomaPhase II, suspended (reason: pending new testing requirements from the FDA)Celldex TherapeuticsNCT03688178
Varlilumab+rituximabFully human IgG1 CD27 agonistic mAb+mAb targeting CD20B-cell lymphomaPhase IIa, recruitingUniversity Hospital Southampton NHS Foundation Trust+Celldex TherapeuticsNCT03307746
Varlilumab+vaccination with 6MHPFully human IgG1 CD27 agonistic mAb+6 melanoma helper vaccine composed of 6 class II MHC-restricted helper peptidesStage II–IV melanomaPhase I/II, recruitingCraig L Slingluff Jr+Celldex TherapeuticsNCT03617328
Cusatuzumab+azacitidineGlycoengineered CD70 blocking mAb+antimetabolite/demethylating agentAMLPhase I+II, recruitingJanssen Research & Development, LLV+Argenx BVBANCT04023526/
NCT04150887
  • AML, acute myeloid leukaemia; CAR-T cell, chimeric antigen receptor gene-modified T cell; CD27, cluster of differentiation 27; CD70, cluster of differentiation 70; DC, dentritic cell; FDA, Food and Drug Administration; mAb, monoclonal antibody; 6MHP, 6 melanoma helper vaccine comprised of 6 class II MHC-restricted helper peptides; NCI, National Cancer Institute; NSCLC, non-small-cell lung cancer; PBL, peripheral blood lymphocytes; PD-L1, programmed cell death 1 ligand 1; poly-ICLC, polyinosinic-polycytidylic acid stabilised with polylysine and carboxymethyl cellulose; RT, radiotherapy; TMZ, temozolomide.